The short answer
New Zealand’s official guidance distinguishes unlawful cannabis cultivation from licensed medicinal cannabis activities and qualifying hemp activities. The material linked here does not describe a general recreational home-growing permission. The important question is which legal framework, if any, covers the particular activity.
This article explains those distinctions using government material checked on 17 September 2026. It is general information, not legal advice or a determination about an individual case. It does not describe cultivation techniques, predict enforcement outcomes or recommend a cannabis product.
The controlled-drug starting point
New Zealand Police identifies cannabis plants and seeds as Class C controlled drugs in its explanation of the Misuse of Drugs Act. Its overview discusses unlawful cultivation, possession and dealing as separate drug offences. A question about growing plants is therefore different from a question about possessing a prescribed product.
The Police explanation of cultivation includes activities involving plants before and after maturity. Its legal description is not confined to a finished product. This article does not reproduce the page’s penalty table or offer an opinion about charges, defences or sentencing.
The key distinction is between an activity being regulated and a particular person having authority for it. Describing cannabis as controlled does not mean every authorised medicinal or hemp activity is prohibited. Equally, the existence of a regulated industry is not evidence of unrestricted permission for ordinary home growing.
New Zealand Police — Illicit drugs: offences and penalties.
Hemp rules changed in May 2026
The Ministry of Health states that the former industrial-hemp licensing scheme was replaced on 28 May 2026. Its current guidance describes a permission-based framework, rather than the previous general domestic licensing scheme. An explanation that still says every domestic hemp activity needs that former licence is out of date.
The Ministry defines hemp by reference to a THC limit of no more than one percent of the plant’s dry weight. It also says the former approved-cultivar list no longer exists. These are descriptions of the regulatory category, not instructions for selecting or producing plants.
The guidance explicitly distinguishes high-THC cannabis from hemp. Seeds, seedlings or other material from a high-THC cultivar are not treated as hemp merely because of their stage of development. The change must therefore be read as a defined hemp reform, not a general legalisation of recreational cannabis.
Ministry of Health — Hemp: current regulatory guidance.
Permission-based does not mean condition-free
The Police hemp guidance describes specified purposes for the new domestic permissions: development of hemp varieties, research into their suitability for hemp products, production of those products, and supply into the Medicinal Cannabis Scheme. The permissions concern qualifying hemp and the purposes described by the rules.
For relevant hemp activities, the Police guidance also describes notification requirements involving Police and the Ministry for Primary Industries. Notifications last one year. The page distinguishes this notification framework from activity under a medicinal cannabis licence.
This is why two short statements can both mislead: that a hemp licence is always needed, or that hemp is now entirely unregulated. The current framework replaced an earlier mechanism while retaining conditions. The official page explains the applicable scope; this article does not assess whether a reader’s proposed activity qualifies or provide instructions for starting it.
New Zealand Police — Cultivating hemp.
The medicinal framework has a separate history
The Ministry’s history of the Medicinal Cannabis Scheme records its commencement on 1 April 2020. It describes the purpose as improving patient access to quality medicinal cannabis products. The scheme’s industry arrangements and its patient-access purpose belong to the same framework, but they address different roles.
The official timeline distinguishes the 2018 medicinal-cannabis amendment legislation, the regulations made in December 2019, and the scheme’s commencement the following April. Those milestones concern the medicinal framework. They should not be confused with the separate 2020 referendum about proposed recreational-cannabis reform.
The history also explains that industry participants operate under licences specifying activities. In this setting, the word medicinal identifies a regulatory system; it is not a free-standing description that turns any cannabis plant into an authorised product. The relevant licence and the patient’s prescription answer different questions.
Ministry of Health — About the Medicinal Cannabis Scheme.
Patient access is about prescribed products
The Ministry’s consumer information says medicinal cannabis products are available on prescription. It directs decisions about suitability to health professionals, who consider a patient’s circumstances and other medicines. This article makes no recommendation about whether a particular product would help any condition.
The consumer guidance discusses different finished-product forms, including dried material and pharmaceutical dosage forms. It explains that CBD products are prescription medicines, while other medicinal cannabis products may also be controlled drugs. The presence of different formulations does not make their regulatory categories interchangeable.
A patient-facing product pathway is different from an industry cultivation licence. That distinction follows from reading the consumer guidance alongside the Ministry’s separate licence descriptions. A prescription is not described in those sources as a cultivation licence. Questions about treatment belong with an appropriate prescriber; questions about an individual’s legal authority need advice addressing that authority.
Ministry of Health — Information for consumers about medicinal cannabis.
A licence identifies particular activities
The Ministry lists five medicinal cannabis licence activities: cultivation, seed supply, research, possession for manufacture, and supply. A licence may authorise one or more of them. Its explanation covers the licence holder and people acting under that holder’s authority, within the regulatory framework.
The list matters because growing, conducting a clinical study and supplying a finished product are not a single legal activity. For example, the research category concerns specified clinical-trial or study activity, whereas possession for manufacture addresses processing and related product-development work. These are descriptions of licence categories, not a practical production guide.
The official index links each category to its own detailed explanation. Reading only the heading cultivation would leave out the separate categories. Similarly, treating a reference to a licence as a universal permission would overlook that the document specifies what it authorises. The actual scope matters more than a general label such as licensed business.
Ministry of Health — Licence activities for medicinal cannabis.
The cultivation category has defined limits
The Ministry’s detailed cultivation page identifies medicinal-product cultivation, certain dealings with other appropriately authorised licence holders, and particular research and export activities within that category. It does not describe unrestricted activity by the public.
The page also separates cultivation research from supplying a product to a person participating in a clinical trial. It assigns the latter to a research activity. That distinction shows why the everyday word research is not enough to identify the relevant authorisation.
Likewise, the Ministry explains that cultivation and manufacturing medicinal products require distinct activities and that medicines-manufacturing requirements may also apply. No manufacturing method is described here. The point is that authority at one part of a regulated chain does not, by itself, describe authority at every other part. This summary deliberately omits application steps, fees, plant allowances and technical production requirements; the official page remains the source for its own detailed scope.
Ministry of Health — Cultivation of medicinal cannabis.
Product quality is another separate question
The minimum-quality-standard guidance distinguishes starting material, cannabis-based ingredients and finished medicinal cannabis products. It sets out where the standard applies, including differences between domestic supply and export, and describes specified exceptions. A general reference to cannabis does not identify which category is being discussed.
The standard addresses matters such as contaminants, ingredient identity, packaging, labelling and stability. The guidance separates tests with maximum limits from other quality requirements and validation of test methods. Those are regulatory quality controls, not instructions for making a product.
Quality terminology should therefore not be substituted for a cultivation authorisation or a clinical recommendation. This article makes no claim that an individual product is verified, suitable or effective. Its narrower point is that the official framework asks several distinct questions: who may undertake an activity, what that activity is, and which requirements apply to the resulting material or product.
Ministry of Health — Requirements for the medicinal cannabis minimum quality standard.
The 2020 referendum was a different event
The Electoral Commission’s final results show that the cannabis referendum proposal did not receive majority support. The official figures were 50.7 percent for No and 48.4 percent for Yes, with informal votes accounting for the remaining 0.9 percent. These were the final results released on 6 November 2020.
The result answers a historical question about that proposal. It is not a substitute for reading a current regulatory framework. The medicinal scheme’s April 2020 commencement and the hemp changes of May 2026 are separate events, documented by their respective official sources.
Keeping these dates separate helps avoid a common misunderstanding: a discussion of what a proposal might have allowed is not a description of an existing permission. This article relies on the published result, not predictions about future votes or reform. It does not suggest that the referendum created a home-growing allowance or that the later hemp changes retrospectively altered the vote.
Electoral Commission — Official referendum results released.
Reading the sources together
The links below each section identify the official material used for that explanation. They cover different questions and should be read within their stated scope. The source-check date records when those pages were examined; it does not freeze the law or certify an individual activity.
The practical conclusion is a distinction, not a blanket permission: ordinary cannabis cultivation, medicinal licence activity and qualifying hemp activity cannot be treated as the same thing. Current primary sources and advice about the actual circumstances are more useful than an unsourced claim that all growing is allowed, or that every form of it follows the old hemp-licensing scheme.